RSLV-132

Home
Ligands
RSLV-132

GtoPdb Ligand ID: 10412

Synonyms: RSLV132

Comment: RSLV-132 is a fully human biologic fusion protein that is comprised of human RNase fused to the Fc domain of human IgG1 [1]. The peptide sequence of RSLV-132 has not yet been formally disclosed. It is designed to digest circulating extracellular RNA autoantigens that are known to trigger inflammatory responses in some chronic autoinflammatory conditions. RSLV-132 is proposed for anti-inflammatory and immunomodulatory activities in such conditions. It may also be effective in reducing viral RNA load and/or persistence in virus reservoirs.

Immunopharmacology Comments
RSLV-132 was designed to breakdown extracellular RNA that circulates in the blood of patients with systemic lupus erythematosus [1], and which is associated with pathogenesis in this condition [4-5]. Decreasing blood-bourne RNA is expected to reduce activation of the B cell receptor/Toll-like receptor 7 pathway to bring about a reduction in inflammatory cytokine production.

Immunopharmacology Comments

RSLV-132 was designed to breakdown extracellular RNA that circulates in the blood of patients with systemic lupus erythematosus [1], and which is associated with pathogenesis in this condition [4-5]. Decreasing blood-bourne RNA is expected to reduce activation of the B cell receptor/Toll-like receptor 7 pathway to bring about a reduction in inflammatory cytokine production.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Systemic lupus erythematosus	Disease Ontology: DOID:9074 OMIM: 152700 Orphanet: ORPHA536	RSLV-132 has progressed to Phase 2 clinical evaluation in SLE patients- see NCT03247686
Sjögren's syndrome	Orphanet: ORPHA378	RSLV-132 has progressed to Phase 2 clinical evaluation in SS patients- see NCT02660944